tirzepatide and nafld alleviates non-alcoholic fatty liver disease by regulating lipid metabolism through activation of the AMPK/NF-κB signaling pathway Dual GIP and GLP-1 receptor

In the case of semaglutide, compounding has expanded access during periods of drug shortage and provided options at different price points than branded products

The Rise in Use Among Youth According to a 2024 article from AAMCNews, prescriptions for GLP-1 medications have surged by 700% among youth from 2022 to 2024, with pediatric bariatric surgeries also rising

Behavioral Therapy: Working with a therapist can help address behaviors and habits related to eating and exercise

Thanks to this holistic effect on the body, Rybelsus helps patients significantly reduce weight and improve metabolic health

Tirzepatide combines GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonism [106]

| Target Concentration | BAC Water to Add | Dose per 10 units on syringe | |---------------------|-----------------|------------------------------| | 6mg/ml | 2.0ml | 0.6mg | | 12mg/ml | 1.0ml | 1.2mg | | 4mg/ml | 3.0ml | 0.4mg | **Best for:** Patients transitioning from 2mg to 4mg weekly doses